Scientific Leadership Group Core

科学领导小组核心

• 批准号: 10595900
• 负责人: Lisa B Hightow-Weidman
• 金额: $ 425.15万
• 依托单位: FLORIDA STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-01-25 至 2029-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10595900
• 关键词: Accountability; Acquired Immunodeficiency Syndrome; Address; Adolescent; Adolescent Medicine Trials Network; Adolescent and Young Adult; Area; Articulation; Bioethics; Caring; Clinical; Clinical Investigator; Clinical Protocols; Clinical Trials; Cognitive; Collaborations; Communication; Community Practice; Development; Discipline; Dissemination and Implementation; Effectiveness; Emotional; Ensure; Epidemic; Equity; Fostering; Funding; Future; Gender Identity; Geography; Goals; HIV; HIV-infected adolescents; HIV/AIDS; Infrastructure; Institution; Interdisciplinary Study; Intervention; Intervention Studies; Intervention Trial; Investments; Knowledge; Leadership; Mentors; Mission; Outcome; Policies; Positioning Attribute; Practice Guidelines; Prevention; Prevention strategy; Problem Solving; Public Health; Publications; Qualifying; Research; Research Activity; Research Personnel; Research Priority; Research Project Grants; Resource-limited setting; Risk; Role; Science; Site; Therapeutic; Training; Translating; Translations; Underrepresented Minority; United States; United States National Institutes of Health; Youth; adolescent HIV prevention; clinical development; clinical practice; co-infection; comorbidity; data management; design; diagnostic technologies; ethnic identity; experience; flexibility; health equity; industry partner; innovation; laboratory equipment; lens; member; mobile computing; multidisciplinary; next generation; operation; policy recommendation; racial identity; resilience; response; sexual identity; social; synergism; therapy design; working group; Accountability; Acquired Immunodeficiency Syndrome; Address; Adolescent; Adolescent Medicine Trials Network; Adolescent and Young Adult; Area; Articulation; Bioethics; Caring; Clinical; Clinical Investigator; Clinical Protocols; Clinical Trials; Cognitive; Collaborations; Communication; Community Practice; Development; Discipline; Dissemination and Implementation; Effectiveness; Emotional; Ensure; Epidemic; Equity; Fostering; Funding; Future; Gender Identity; Geography; Goals; HIV; HIV-infected adolescents; HIV/AIDS; Infrastructure; Institution; Interdisciplinary Study; Intervention; Intervention Studies; Intervention Trial; Investments; Knowledge; Leadership; Mentors; Mission; Outcome; Policies; Positioning Attribute; Practice Guidelines; Prevention; Prevention strategy; Problem Solving; Public Health; Publications; Qualifying; Research; Research Activity; Research Personnel; Research Priority; Research Project Grants; Resource-limited setting; Risk; Role; Science; Site; Therapeutic; Training; Translating; Translations; Underrepresented Minority; United States; United States National Institutes of Health; Youth; adolescent HIV prevention; clinical development; clinical practice; co-infection; comorbidity; data management; design; diagnostic technologies; ethnic identity; experience; flexibility; health equity; industry partner; innovation; laboratory equipment; lens; member; mobile computing; multidisciplinary; next generation; operation; policy recommendation; racial identity; resilience; response; sexual identity; social; synergism; therapy design; working group

PROJECT SUMMARY The Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) fills a unique role among the NIH- funded networks by bringing together scientific and clinical investigators with the requisite knowledge and experience to design and implement interdisciplinary, developmentally appropriate prevention strategies for youth living with HIV and those at-risk in the United States (US). An experienced, multidisciplinary, and visionary Scientific Leadership Group (SLG) is needed who is poised to develop, refine, and support both an established and emerging ATN scientific agenda that impacts the HIV epidemic among youth domestically. Seamless collaboration will be essential at all levels, expecting and requiring innovation from investigators invested in addressing the significant challenges and seizing opportunities within the field of adolescent HIV prevention and care research. Efficient and effective communication strategies to accomplish high-impact research obligates synergies between the ATN SLG and Scientific Leadership Center (SLC), the Statistical and Data Management Core (SDMC), the Operations and Collaborations Center (OCC), the Research Project teams, Site Consortiums and NIH and industry partners. The SLG, working collaboratively with the SLC, SDMC, OCC and NIH is poised to actuate the unique mission, strengths, and expertise housed within the ATN, to identify gaps in the ATN research portfolio, and to form additional strategic partnerships that ensure the ATN’s swift response to high priority and emergent research areas. Given the broad ATN agenda, we have formulated a strong, interdisciplinary SLG which includes the world’s experts in all areas relevant to ending the HIV epidemic among adolescents in the US. This team consists of investigators with diverse expertise and experiences, including diversity in terms of race/ethnicity, sexual and gender identity, HIV-status, geography, discipline, and training. Building upon years of collective experience, Drs. Hightow-Weidman and Hosek will provide the necessary leadership and infrastructure to support the SLG to develop and refine the research agenda of the ATN, convene working groups as needed, prioritize emerging research projects, efficiently manage the development of clinical protocols, implement, and complete clinical trials and ensure timely publication and communication of results. Drs. Hightow-Weidman and Hosek aim to use an approach toward management of the SLG, honed through decades of prior ATN and clinical trials experiences, that will foster innovation and effectiveness through flexibility, open communication between all SLG team members, mutual respect, collective problem solving, and shared accountability. The SLG is configured through Leadership Teams organized around six areas: Biomedical Therapeutics, Comorbidities and Coinfections, Laboratory, Diagnostics and Mobile Technologies, Institutions, Organizations and Policy, Equity, Inclusion, and Engagement, and Risk and Resilience, and supported by a Bioethics Committee. These content areas encompass the areas of focus required to truly catalyze multidisciplinary research and translate the findings to ensure maximum clinical and policy impact by the ATN.

项目摘要 艾滋病毒/艾滋病干预措施（ATN）的青少年医学试验网络（ATN）填补了NIH- 通过将科学和临床研究人员汇集到必要的知识以及 设计和实施跨学科，发展适当的预防策略的经验 与艾滋病毒和美国高风险的年轻人（美国）。经验，多学科和有远见的人 需要科学领导力小组（SLG） 以及新兴的ATN科学Agernda，在国内影响青年的艾滋病毒流行。无缝的 在各个层面上，协作将是必不可少的，期望并要求调查人员的创新 应对青少年艾滋病毒预防领域的重大挑战和抓住机会 护理研究。实现高影响力研究的高效有效的沟通策略义务 ATN SLG与科学领导力中心（SLC）之间的协同作用，统计和数据管理 核心（SDMC），运营与合作中心（OCC），研究项目团队，现场财团 NIH和行业合作伙伴。 SLG与SLC，SDMC，OCC和NIH合作合作 启动ATN中包含的独特任务，优势和专业知识，以确定ATN中的空白 研究组合，并建立其他战略合作伙伴关系，以确保ATN迅速对高的反应 优先和新兴研究领域。鉴于广泛的ATN Agernda，我们已经制定了一个强大的 跨学科的SLG包括与结束与结束艾滋病毒流行有关的世界专家 美国的青少年。该团队由具有潜水专业知识和经验的调查员组成，包括 在种族/种族，性别和性别认同，HIV状态，地理，纪律和培训方面的多样性。 基于多年的集体经验，博士。 Hightow-Weidman和Hosek将提供必要的 领导和基础设施支持SLG制定和完善ATN的研究议程 根据需要的工作组，优先考虑新兴研究项目，有效地管理临床的发展 协议，实施和完成临床试验，并确保及时发布和沟通结果。 博士。 Hightow-Weidman和Hosek的目标是利用SLG管理的方法 数十年的先前ATN和临床试验经验，这些经验将通过 灵活性，所有SLG团队成员之间的公开沟通，相互尊重，集体问题解决以及 共同的问责制。 SLG是通过在六个领域组织的领导团队配置的：生物医学 治疗，合并症和共同感染，实验室，诊断和移动技术，机构，机构， 组织和政策，公平，包容和参与以及风险和韧性，并由 生物伦理学委员会。这些内容领域包括真正催化的重点领域 多学科研究并翻译发现，以确保ATN的最大临床和政策影响。